Despite a slight decline from July, South Korea’s current account balance in August was in surplus at $6.6 billion, reflecting steady export growth, and the financial account showed an increase in net assets. It is a characteristic. In this context, high-growth tech stocks like Samsung Biologics are in the spotlight as investors look for companies that can leverage strong export performance and effectively navigate complex global market conditions. are.
Top 10 high-growth technology companies in South Korea
name
increase in revenue
revenue growth
growth assessment
IML Co., Ltd.
21.80%
111.43%
★★★★★
Sojin System Co., Ltd.
33.39%
49.13%
★★★★★
Bioneer
23.53%
97.58%
★★★★★
nexon games
29.64%
66.98%
★★★★★
frit
32.60%
106.82%
★★★★★
Arteogen
64.22%
99.46%
★★★★★
fat sisters
29.08%
63.02%
★★★★★
park system
23.21%
34.63%
★★★★★
AmoSense Co., Ltd.
24.04%
71.97%
★★★★★
urinary tract infection
114.97%
134.60%
★★★★★
Click here to see the complete list of 48 stocks in the KRX High Growth Technology Stock and AI Stock Screener.
Below that, you will see a selection of stocks filtered by the screen.
Simply Wall Street Growth Rating: ★★★★☆
Overview: Medy-Tox Inc. is a Korean biopharmaceutical company with a market capitalization of 1.19 trillion won.
Business Operations: The company’s main source of revenue is its biotechnology division, generating 246.25 billion won.
Medytox announces share buyback program to stabilize share price and increase shareholder value in the midst of a difficult year in which profits fell 82.2%, with plans to buy back up to 16,008 shares by end of December 2024 is standing. , the company’s revenue growth outlook remains positive at 12.2% per year, higher than the Korean market average of 10.5%. Additionally, Medy-Tox is expected to see a significant revenue recovery with an expected annual growth rate of 62% over the next three years. This strategic shift towards stabilizing financial metrics while fostering significant future growth encapsulates an adaptive approach in navigating market dynamics.
KOSDAQ:A086900 Revenue and revenue growth as of October 2024
Simply Wall Street Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobettors, proprietary antibody-drug conjugates, and antibody biosimilars, with a market capitalization of KRW 19.6 trillion.
Business Operations: The company mainly generates revenue through its biotechnology division, which amounts to KRW 90.79 billion. Its focus on developing innovative biotechnology solutions positions the company in the niche market of long-acting biobettors and antibody biosimilars.
the story continues
In the dynamic landscape of South Korea’s high-tech industry, ALTEOGEN stands out for its aggressive investment in research and development, devoting a significant portion of its revenues to innovation. This strategy is evidenced by strong annual increases in research and development spending, consistent with the company’s vision to lead the way in biotechnology advances. Despite the current unprofitability, ALTEOGEN’s revenue is projected to grow 64.2% annually, significantly outpacing the overall market growth rate of 10.5%. Additionally, revenue is expected to jump approximately 99.5% annually over the next three years, reflecting significant financial improvements and potential market impact. This growth trajectory highlights ALTEOGEN’s commitment to evolution in the high-tech sector and suggests promising prospects for ALTEOGEN’s role in shaping the future technological landscape.
KOSDAQ:A196170 Breakdown of revenue and expenses as of October 2024
Simply Wall Street Growth Rating: ★★★★☆
Overview: HYBE Co., Ltd. is involved in music production, publishing, artist development and management, and has a market capitalization of 7.44 trillion won.
Business Operations: HYBE mainly generates revenue from its label and solutions segments, which contribute 1.28 trillion won and 1.24 trillion won, respectively. The platform division will further increase the company’s revenue stream by 361.12 billion won.
HYBE, a South Korean entertainment powerhouse, has demonstrated a strong commitment to innovation through R&D investments. In 2024 alone, the company allocated 14% of its revenue to new technology and content enhancements and development. This strategic focus is reflected in solid earnings forecasts, with annual growth expected to be 42.2%, well ahead of the broader market expectation of 30.6%. Additionally, HYBE recently completed a share buyback program and bought back 26 billion won worth of shares to stabilize the stock price. This move confirms confidence in the company’s financial health and future prospects.
KOSE:A352820 Breakdown of revenue and expenses as of October 2024
Where are you going now?
Interested in other options?
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
Companies mentioned in this article include KOSDAQ:A086900, KOSDAQ:A196170, and KOSE:A352820.
Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.
